Printer Friendly

AXCELL DEBUTS PROCHART PROTEIN INTERACTIONS DATABASE.

The new ProChart Database of protein interactions in the human body has been introduced in Europe by AxCell Biosciences Corporation, a subsidiary of Cytogen Corporation (Nasdaq: CYTO), and InforMax, Inc (Nasdaq: INMX).

The database includes the results of AxCell's successful effort to map all of the interactions of one of the body's 60- 80 protein domain families. In January, 2001, AxCell announced the completion of the map of the WW Protein Domain, which is believed to have an impact on health problems including hypertension, muscular dystrophy and immunodeficiency. AxCell is working to complete the map of all signal transduction protein interactions in the human body within four years.

In March, AxCell introduced ProChart in six cities across the United States using InforMax's Protein-Protein Interaction Analysis (PPI) module, which will be available in the next release of the GenoMax(TM) enterprise bioinformatics platform, the proprietary advanced bioinformatics software from InforMax.

ProChart is a database of protein-to-protein interactions, created using AxCell's patented, high-throughput technology, which differs from the most widely used method for studying protein interactions called yeast two-hybrid (Y2H). InforMax is currently marketing the ProChart Database to the pharmaceutical and biotechnology industries through multi-year subscriptions.

Marketing activities for ProChart in Europe began with presentations at IBC's Drug Discovery Technology 2001, the multidisciplinary biopharmaceutical conference held April 23-26 in Stuttgart, Germany. AxCell has also again participated in a seminar series with its marketing partner, InforMax.

Scientists at AxCell identified more than 69,000 different protein interactions of the WW domain, the name for one of the human body's specific family of proteins and the initial family offered to ProChart database subscribers. In the future, AxCell anticipates adding PDZ and SH3, two domain families involved with diseases such as stroke, Alzheimer's, diabetes, cancer, HIV and osteoporosis. The company will also chart increasingly greater portions of the proteome and add these results to ProChart. Subscription rates will be based on the amount and quality of data available.

"We have been quite pleased with the interest in ProChart in the U.S.," said Brian R. Bullard, vice president and chief information officer of AxCell Biosciences. "Our technology can positively impact numerous steps in research and development, such as target identification and validation, which we believe will offer high value to ProChart customers."

In addition to the high-profile Drug Discovery Technology 2001 conference, AxCell will be presenting at a number of events, such as Cambridge Healthtech's HTT Expo in Philadelphia this month and Beyond Genome 2001 Conference in San Francisco, also in June. InforMax is continuing with the U.S. marketing activities for ProChart in the United States, with initial sales contacts and follow-up scheduled for the remainder of 2001.

About Cytogen

Cytogen Corporation is a biopharmaceutical company based in Princeton, NJ. The company has two principal lines of business: a product-based oncology focus and a proteomics drug discovery platform. Cytogen's expertise in monoclonal antibodies and molecular recognition are directed principally to the development of novel products for the diagnosis, imaging, staging and treatment of prostate cancer and a proteomics-driven drug discovery platform. For information regarding currently marketed oncology products and general corporate information, visit http://www.cytogen.com.

About AxCell Biosciences

AxCell Biosciences, a subsidiary of Cytogen Corporation, is a leader in the effort to chart protein-signaling pathways in the human proteome as a means of discovering new drug targets. AxCell is developing a proprietary protein-pathway database, the ProChart(TM) database as a discovery and development tool for subscribers in the pharmaceutical, biotechnology and agricultural industries. For additional information on AxCell Biosciences, visit http://www.axcellbio.com.

About InforMax

InforMax is a leading global developer of bioinformatics software for High-Throughput Research(TM). InforMax products are used by more than 1650 research organizations and more than 22,000 individual scientists worldwide (as of December 31, 2000) to understand and extract value from the massive amounts of data being generated by the Genomic Revolution. Among the company's customers are 22 of the top 25 pharmaceutical companies. InforMax was founded in 1990 by Alex Titomirov, Ph.D. Its mission is to speed the pace of medical progress by enabling High-Throughput Research(TM), a process for compressing the time it takes to discover and validate the biological targets most likely to result in breakthrough therapeutics, diagnostics or biomolecular interventions to cure or prevent disease.

InforMax bioinformatics software solutions enable a full range of gene-to-genome analysis, interpretation and data mining. Its market-leading products include Vector NTI(R) Suite, the most widely used software suite for enhancing laboratory productivity, and GenoMax(TM) for integrated analysis of genomic and proteomic data. Additional information about InforMax can be found at the company's Web site at http://www.informaxinc.com.

For more information, call 212-279-2060.
COPYRIGHT 2001 Worldwide Videotex
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2001 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Worldwide Databases
Date:Jun 1, 2001
Words:781
Previous Article:LEXIS-NEXIS LAUNCHES CORPORATE LINKAGE DB ON WEB.
Next Article:IBM TO ACQUIRE INFORMIX DATABASE BUSINESS.
Topics:


Related Articles
CURAGEN GETS PATENTS ON INTERACTIONS IMPLICATED IN CANCER.
MAP OF WW PROTEIN DOMAIN HELPS TARGET HEALTH PROBLEMS.
Europe: The European Commission has announced plans to invest 19.4 million [European Dollar] ($17.2 million at $1 = 1.13 [European Dollar]) in...
AxCell Biosciences Enters Into Research Collaboration.
AXCELL/MUENSTER ALLIANCE TO RESEARCH PROTEIN INTERACTIONS.
Random samples: companies.
AXCELL EXPLORES DISEASE PATHWAYS USING IBM DB2 TECHNOLOGY.
NEW TECHNOLOGY HELPS DRUG COMPANIES DESIGN SAFER DRUGS.
SAB introduces beer portfolio to American press.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters